Tarsus Pharmaceuticals, Inc. TARS
6 trading plans running, 48 Form 144 notices for $36.8M
10-Q, 10-K and Form 144What TARS's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Nov 13, 2025 to Sep 10, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Andrew Goldberg Board of Directors |
Adopted 10b5-1 plan | Sep 11, 2026 | 10-Q Nov 3, 2026 | ||
What the company wroteOn September 11, 2026, Andrew Goldberg, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement (the “Goldberg Plan”) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The Goldberg Plan provides for the potential sale of up to 13,700 shares of common stock held by Mr. Goldberg between December 11, 2026 and January 4, 2027. The Goldberg Plan also provides for the sale of up to 20,000 shares of common stock that will be acquired through the cashless exercise of non-qualified stock options, between December 11, 2026 and September 10, 2027. | |||||
| Elizabeth Yeu-Lin Chief Medical Officer |
Adopted 10b5-1 plan | Jun 1, 2026 | 10-Q Aug 6, 2026 | ||
What the company wroteOn June 1, 2026, Elizabeth Yeu-Lin, our Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement (the “Yeu-Lin Plan”) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The Yeu-Lin Plan provides for the potential sale of up to 9,506 shares of common stock held by Ms. Yeu-Lin between September 1, 2026 and August 31, 2027. | |||||
| spouse of Ms. Yeu-Lin | Adopted 10b5-1 plan | Jun 1, 2026 | 10-Q Aug 6, 2026 | ||
What the company wroteAlso on June 1, 2026, the spouse of Ms. Yeu-Lin adopted a Rule 10b5-1 trading arrangement (the “Spousal Plan”) covering shares of the Company's common stock in which Ms. Yeu-Lin has an indirect pecuniary interest reportable under Section 16 of the Exchange Act. The Spousal Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and provides for the potential sale of up to 6,360 shares of the Company's common stock, between September 1, 2026 and September 1, 2027. | |||||
| Katherine Goodrich Board of Directors |
Adopted 10b5-1 plan | Mar 2, 2026 | 10-Q May 6, 2026 | ||
What the company wroteOn March 2, 2026, Katherine Goodrich, a member of our Board of Directors, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 5,187 shares of common stock held by Ms. Goodrich between June 12, 2026 and June 2, 2027. | |||||
| Seshadri Neervannan Chief Operating Officer |
Adopted 10b5-1 plan | Nov 13, 2025 | 10-K Feb 23, 2026 | ||
What the company wroteIn December 2025, Dr. Azamian, adopted a new Rule 10b5-1 trading plan. The plan provides for the sale of up to 60,000 shares of common stock held by Dr. Azamian between March 24, 2026 and March 24, 2027. On November 13, 2025, Seshadri Neervannan, our Chief Operating Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 18,027 shares of common stock held by Dr. Neervannan between March 4, 2026 and March 16, 2026. | |||||
| Jose Trevejo former Chief Medical Officer |
Ended 10b5-1 plan | Jan 12, 2024 | 10-Q May 8, 2024 | ||
What the company wroteIn May 2023, Jose Trevejo, former Chief Medical Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the sale of up to 6,107 shares of common stock held by Dr. Trevejo between August 17, 2023 and May 16, 2024. Dr. Trevejo terminated the trading plan effective January 12, 2024. | |||||
| Bobak Azamian Chief Executive Officer |
Ended 10b5-1 plan | Jan 8, 2024 | 10-Q May 8, 2024 | ||
What the company wroteIn May 2023, Bobak Azamian, Chief Executive Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the sale of up to 291,000 shares of common stock held by Dr. Azamian between August 23, 2023 and July 24, 2024. Dr. Azamian terminated the trading plan effective January 8, 2024. | |||||
| Aziz Mottiwala Chief Commercial Officer |
Adopted 10b5-1 plan | – | 10-Q May 1, 2025 | ||
What the company wroteIn March 2025, Aziz Mottiwala, our Chief Commercial Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 17,500 shares of common stock held by Mr. Mottiwala between June 9, 2025 and June 9, 2026. | |||||
| Bobak Azamian Chief Executive Officer |
Adopted 10b5-1 plan | – | 10-K Feb 25, 2025 | ||
What the company wroteIn December 2024, Bobak Azamian, our Chief Executive Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 24,000 shares of common stock held by Dr. Azamian between March 24, 2025, and March 23, 2026. | |||||
| Dianne Whitfield Chief Human Resources Officer |
Adopted 10b5-1 plan | – | 10-Q Nov 4, 2025 | ||
What the company wroteIn September 2025, Dianne Whitfield, our Chief Human Resources Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 57,925 shares of common stock held by Ms. Whitfield between December 16, 2025 and April 1, 2026. | |||||
| Dr. Azamian | Adopted 10b5-1 plan | – | 10-K Feb 23, 2026 | ||
| William Link Board of Directors |
Adopted 10b5-1 plan | – | 10-Q Nov 4, 2025 | ||
What the company wroteIn September 2025, William Link, a member of our Board of Directors, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 50,000 shares of common stock held by Dr. Link between December 15, 2025 and December 14, 2026. | |||||
Show the other 4 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 13, 2026 | Bobak Azamian Officer |
10,000 | $802K |
| Sep 15, 2026 | WILLIAM J LINK DIRECTOR |
12,500 | $980K |
| Sep 4, 2026 | Lin Elizabeth Yeu Member of immediate family of any of the foregoing |
3,180 | $278K |
| Sep 4, 2026 | Lin Elizabeth Yeu Officer |
10,773 | $943K |
| Sep 4, 2026 | Neervannan Seshadri Officer |
4,564 | $388K |
| Sep 4, 2026 | BOBAK AZAMIAN OFFICER |
10,000 | $906K |
| Sep 2, 2026 | Lin Elizabeth Yeu Member of immediate family of any of the foregoing |
1,590 | $127K |
| Sep 2, 2026 | Mottiwala Aziz Former Officer |
8,000 | $654K |
| Sep 2, 2026 | Lin Elizabeth Yeu Officer |
5,387 | $431K |
| Sep 2, 2026 | BOBAK AZAMIAN OFFICER |
10,000 | $801K |
| Sep 1, 2026 | Mottiwala Aziz Former Officer |
77,698 | $5.7M |
| Sep 1, 2026 | Lin Elizabeth Yeu Officer |
4,601 | $340K |
| Aug 25, 2026 | Mottiwala Aziz Former Officer |
81,332 | $5.8M |
| Aug 19, 2026 | Mottiwala Aziz Former Officer |
53,043 | $3.8M |
| Jun 17, 2026 | BOBAK AZAMIAN OFFICER |
10,000 | $615K |
| Jun 16, 2026 | Farrow Jeffrey S Officer |
14,396 | $877K |
| Jun 15, 2026 | Goodrich Katherine Director |
2,954 | $183K |
| Jun 15, 2026 | William J Link Director |
12,500 | $776K |
| Mar 20, 2026 | Neervannan Seshadri Officer |
2,989 | $200K |
| Mar 19, 2026 | Farrow Jeffrey S Officer |
2,186 | $146K |
| Mar 19, 2026 | Mottiwala Aziz Officer |
4,440 | $297K |
| Mar 19, 2026 | Azamian Bobak R. Officer, Director |
11,964 | $802K |
| Mar 19, 2026 | Whitfield Dianne C. Officer |
4,174 | $280K |
| Mar 19, 2026 | Wahl Bryan Officer |
4,231 | $283K |
| Mar 19, 2026 | Neervannan Seshadri Officer |
4,589 | $307K |
| Mar 19, 2026 | Lin Elizabeth Yeu Officer |
390 | $26K |
| Mar 18, 2026 | Whitfield Dianne C. Officer |
4,071 | $280K |
| Mar 18, 2026 | Wahl Bryan Officer |
4,125 | $283K |
| Mar 18, 2026 | Azamian Bobak R. Officer, Director |
11,667 | $802K |
| Mar 18, 2026 | Neervannan Seshadri Officer |
3,610 | $248K |
| Mar 18, 2026 | Farrow Jeffrey S Officer |
2,133 | $147K |
| Mar 18, 2026 | Mottiwala Aziz Officer |
4,330 | $298K |
| Mar 18, 2026 | Lin Elizabeth Yeu Officer |
379 | $26K |
| Mar 17, 2026 | Azamian Bobak R. Officer, Director |
10,972 | $762K |
| Mar 17, 2026 | Neervannan Seshadri Officer |
3,125 | $217K |
| Mar 17, 2026 | Farrow Jeffrey S Officer |
2,111 | $147K |
| Mar 17, 2026 | Wahl Bryan Officer |
4,084 | $283K |
| Mar 17, 2026 | Whitfield Dianne C. Officer |
4,029 | $280K |
| Mar 17, 2026 | Lin Elizabeth Yeu Officer |
375 | $26K |
| Mar 17, 2026 | Mottiwala Aziz Officer |
4,286 | $298K |
| Mar 16, 2026 | WILLIAM J LINK DIRECTOR |
12,500 | $860K |
| Mar 4, 2026 | Neervannan Seshadri Officer |
8,366 | $641K |
| Jan 2, 2026 | Whitfield Dianne C. Officer |
15,565 | $1.3M |
| Dec 29, 2025 | BOBAK AZAMIAN OFFICER |
6,000 | $495K |
| Dec 16, 2025 | Lin Elizabeth Yeu Officer |
2,078 | $165K |
| Dec 16, 2025 | Whitfield Dianne C. Officer |
7,397 | $592K |
| Dec 15, 2025 | William Link Director |
10,446 | $846K |
| Dec 15, 2025 | WILLIAM J LINK DIRECTOR |
12,500 | $1.0M |
Show the other 40 notices
From the Form 144 XML filed with the SEC, since Dec 15, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TARS/export.csv") into a cell.